Shire Pharmaceuticals Acquires Ferrokin BioSciences for $325,000,000
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0cf873b6-a41c-4fbd-92b4-94649f3652ba&Preview=1 -
Date
3/15/2012 -
Company Name
Ferrokin BioSciences -
Mailing Address
2729 Debbie Court San Carlos, CA 94070 -
Company Description
FerroKin BioSciences is a clinical stage biotechnology company based in the San Francisco Bay Area and focused on developing chelation therapies for a broad range of clinical indications. -
Website
http://www.ferrokin.com -
Transaction Type
M&A -
Transaction Amount
$325,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Shire has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
